Clark Capital Management Group Inc. purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 1,275 shares of the pharmaceutical company’s stock, valued at approximately $235,000.

Other large investors have also recently made changes to their positions in the company. Resources Investment Advisors Inc. bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $27,000. Oregon Public Employees Retirement Fund boosted its holdings in Vertex Pharmaceuticals by 16,530.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after acquiring an additional 4,583,156 shares in the last quarter. We Are One Seven LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $32,000. Berman Capital Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. Finally, FTB Advisors Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1,618.2% in the first quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 178 shares in the last quarter. Institutional investors and hedge funds own 94.92% of the company’s stock.

Shares of VRTX opened at $172.37 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.66. The company has a market cap of $43.22 billion, a P/E ratio of 60.91, a price-to-earnings-growth ratio of 2.45 and a beta of 1.56. Vertex Pharmaceuticals Incorporated has a 12 month low of $144.07 and a 12 month high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.49. The company had revenue of $857.00 million during the quarter, compared to the consensus estimate of $853.00 million. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. Vertex Pharmaceuticals’s revenue was up 34.3% on a year-over-year basis. During the same period last year, the business posted $0.76 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current year.

A number of research analysts have recently weighed in on VRTX shares. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. They noted that the move was a valuation call. Credit Suisse Group started coverage on Vertex Pharmaceuticals in a report on Monday. They issued an “outperform” rating and a $209.00 target price on the stock. Svb Leerink restated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, March 19th. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Oppenheimer raised their target price on Vertex Pharmaceuticals from $200.00 to $230.00 and gave the company an “outperform” rating in a report on Thursday, March 7th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $203.62.

In related news, CMO Reshma Kewalramani sold 241 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $165.41, for a total transaction of $39,863.81. Following the completion of the sale, the chief marketing officer now directly owns 13,736 shares of the company’s stock, valued at $2,272,071.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey M. Leiden sold 10,480 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $175.08, for a total value of $1,834,838.40. The disclosure for this sale can be found here. Insiders have sold 51,247 shares of company stock valued at $8,998,147 over the last ninety days. 0.70% of the stock is currently owned by company insiders.

WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2019/05/23/clark-capital-management-group-inc-takes-235000-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Article: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.